Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Note: This episode was briefly published with an incorrect audio file, which has since been corrected.

FDA is prepared to approve psychedelic therapies for chronic psychiatric disorders before sponsors have fully determined how long the effects last or when patients should receive second or subsequent doses. On the latest BioCentury This Week podcast, BioCentury's analysts assess the latest guidance on psychedelics from FDA.
The team also discusses takeaways from Michael Davis' first interview as CDER director, plus preclinical advances positioning suppressor tRNA for Duchenne, cystic fibrosis, and other nonsense-mutation diseases. They also highlight Emerging Company Profiles on BrainChild and Cloverleaf.

View full story: https://www.biocentury.com/article/660792

#Psychedelics #FDA #GeneTherapy #ClinicalTrials #DrugDevelopment

0:00 - Introduction
1:13 - Psychedelics at FDA
10:20 - Mike Davis Leads CDER
22:29 - Suppressor tRNAs Advance

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text